Brind.

Co-Diagnostics Seeks FDA Clearance Amid Clinical Study Advancements

71 reports, 27 independent Updated Sep 21
Gone quiet Reached 15 outlets in its first 24 hours
Reports
71
Developments
40
Repetition
72%

New informationRepeats or wire copies

AI-generated briefing. Brind wrote this from the reports listed below and has updated it as the story developed. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 27 independent outlets

Co-Diagnostics is currently seeking specific FDA clearance while trading on Nasdaq. The company is also advancing clinical studies and seeking US regulatory review from the FDA. The FDA requires rigorous clinical validation for the drug development pipeline to achieve market entry.

From newsroomamerica.com

Why it matters

Some supportBrind's analysis of the reports

The company's market status is tied to its listing on the Nasdaq Stock Market. Successful navigation of the FDA review process is crucial for the company to achieve market entry for its products.

From newsroomamerica.com

Who's involved

  • FDAThe Food and Drug Administration is the body reviewing the company's drug development applications.
  • CompanyDirect Mail Division of FSSI is the company seeking regulatory review and trading on the Nasdaq.
  • NasdaqNasdaq is the electronic stock exchange where the company is listed.

How it developed

Newest first. Tap a step to see who reported it.
  1. A partnership with BARDA has accelerated the development of SCY-247 for the company.Sub-event
  2. A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.Sub-event
  3. Approval leads to procurement process initiation.Sub-event
  4. UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.Sub-event
  5. BioPorto is seeking regulatory pathways and activating its first clinical site in collaboration with Massachusetts General Hospital.Sub-event
  6. Co-Diagnostics is expanding globally and seeking specific FDA clearance while trading on Nasdaq.1 source
  7. Veradermics, Incorporated is seeking federal regulatory approval from the FDA for its drug candidates.Sub-event
  8. Oversight failures and regulatory inertia in the U.S. drug approval process were exposed on August 3rd, involving the FDA and Merck.Sub-event
Show 32 earlier steps
  1. Co-Diagnostics is advancing clinical studies and seeking US regulatory review from the FDA.1 source
  2. Apnimed, a company based in Massachusetts, is seeking FDA approval for its drug candidates targeting the OSA market and is also planning an IPO to fund operations.Sub-event
  3. The FDA requires rigorous clinical validation for the drug development pipeline to achieve market entry.1 source
  4. Discussion focuses on drug approval processes and policy shifts involving FDA and Penn State Harrisburg.1 source
  5. A clinical trial site is located in West Haven, Rhode Island, with FDA rejection influencing the trial design.Sub-event
  6. The FDA granted IND clearance for Flare Therapeutics Inc.'s prioritized programs.Sub-event
  7. The FDA has approved bemotrizinol as a new sunscreen ingredient, a development that follows years of advocacy by groups like the EWG and its use in Europe.Sub-event
  8. Teva's asset received FDA Orphan Drug and Fast Track designations after announcing an acquisition from Tel Aviv.Sub-event
  9. A study involving Sue Sisley is progressing, having received taxpayer funding from the state legislature and facing the FDA's licensing requirements.Sub-event
  10. The FDA has delayed the clearance process for the TriNav Advance product of TriSalus Life Sciences Inc.Sub-event
  11. The FDA is reviewing a drug approval application for a condition involving the company GAD.Sub-event
  12. GSK and AstraZeneca are seeking FDA approval for new specialty medicines amid market competition.Sub-event
  13. 60 Degrees Pharmaceuticals is seeking MUMS designation from the FDA for its drug tafenoquine.Sub-event
  14. The FDA is involved as Merck starts trials for a cystic fibrosis medicine developed with Vertex, leading to drug access agreements in Denmark and Ireland.Sub-event
  15. OKYO Pharma is planning meetings with the FDA regarding next steps for its clinical trials being conducted in Boston.Sub-event
  16. Revelation Biosciences, Inc. plans to engage the FDA regarding approval pathways and has enrolled cohorts in a clinical study in the US.Sub-event
  17. Merck & Co. received FDA approval for Doravirine and is conducting clinical studies in Kenya, South Africa, and Uganda, supported by the Gates Foundation.Sub-event
  18. EyePoint Pharmaceuticals developed its LUCIA trial program in alignment with the FDA, with enrollment noted in Lugano.Sub-event
  19. Modular is seeking FDA approval for human use validation after conducting trials under US IRB approval.Sub-event
  20. Alnylam Pharmaceuticals received regulatory approval for its lead drug in both the US and Europe.Sub-event
  21. FDA accepted the company's response to the Complete Response Letter (CRL) for the drug CARDAMYST.Sub-event
  22. Monopar Therapeutics, having taken over sponsorship of ALXN1840 from Alexion, is enrolling in clinical trials and must comply with federal regulations.Sub-event
  23. Vicarious Surgical plans to submit a de novo filing to the FDA, and Fromm has been appointed as its new CEO.Sub-event
  24. Immuneering submitted a meeting request to the FDA regarding its therapies.Sub-event
  25. FDA lifted clinical hold on MARIO study and transferred the BREXAFEMME NDA to GSK.Sub-event
  26. FDA granted Breakthrough Therapy designation for LX2006, a therapy from Lexeo Therapeutics.Sub-event
  27. Palvella Therapeutics is seeking FDA approval for therapies developed using SELVA and Toiva trials.Sub-event
  28. Shattuck Labs, Inc. announced that it submitted an IND application to the FDA, with Taylor Schreiber serving as CEO and OrbiMed leading the recent private placement.Sub-event
  29. Cellectar Biosciences received Breakthrough Therapy Designation from the FDA for its drug iopofosine I 131.Sub-event
  30. Allogene Therapeutics announced the activation of clinical trials across the U.S. and Canada, aligning with the FDA on pivotal trial design.Sub-event
  31. Spectral AI submitted its DeepView diagnostic to the FDA and filed Form 10-Q with the Securities and Exchange Commission (Bangladesh).Sub-event
  32. FDA assisted ENDRA Life Sciences in achieving statistical power for a De Novo submission.Sub-event

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • newsroomamerica.com
  • wtug.com
  • kunc.org
  • prnewswire.com
  • dailypolitical.com
  • wrdw.com
  • finanznachrichten.de
  • themarketsdaily.com
  • lawstreetmedia.com
  • azorobotics.comThe Ultimate Guide to AI and Robotics in Healthcare: From Diagnosis to Autonomous Intervention
  • psu.edu
  • finanznachrichten.de
  • moneycontrol.com
  • manilatimes.net
  • ruthfullyyours.com
  • manilatimes.net
  • prnewswire.com
  • manilatimes.net
  • manilatimes.net
  • prnewswire_fairwayOrexo announces positive outcome from an in-vivo study of OX390
  • prnewswire_crosscountryHALPER SADEH LLC ENCOURAGES AVDL, MBCN, FMNB SHAREHOLDERS TO ENFORCE THEIR RIGHTS AND CONTACT THE LAW FIRM
  • SEC EDGAR (COMP)EX-10.1
  • ZacksAQST Stock Up as FDA Skips Advisory Meeting to Discuss Anaphylm NDA Aquestive Therapeutics AQST announced that the FDA has informed that no advisory committee meeting is required to discuss the new d
  • GlobeNewswireGelteq Announces Commencement of Preclinical Trial for Novel Gel-Based Antihistamine Formulation Targeting Allergy Market Study to Support Potential FDA Approval via 505(b)(2) Pathway MELBOURNE, Aust
  • GlobeNewswireNutriband Inc. announces exercise of warrants at $6.43 for Gross Proceeds of $5,306,000 ORLANDO, Fla., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged
  • GlobeNewswireOpus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Co
  • GlobeNewswireC4 Therapeutics Highlights Recent Achievement in Biogen Collaboration Development Candidate Targeting IRAK4 Now Progressing Toward Clinical Development WATERTOWN, Mass., Sept. 04, 2025 (GLOBE NEWSWIR
  • GlobeNewswireTG Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference Fireside chat scheduled for Monday, September 8, 2025, at 10:30am ET NEW YORK, Sept. 04, 2025 (GLOBE NEW
  • GlobeNewswireGrace Therapeutics Announces Presentation at The H.C. Wainwright 27th Annual Global Investment Conference PRINCETON, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (
  • Simply Wall St.Medtronic (MDT) Expands MiniMed System To Type 2 Diabetes With FDA Approvals Medtronic recently achieved significant FDA regulatory milestones with its MiniMed™ 780G system, notably enhancing its dia
  • Business WireLantern Pharma Announces Completion of Type C Meeting with FDA, Providing Clarity on Regulatory Pathway for Pediatric CNS Cancer Trial DALLAS, September 03, 2025--(BUSINESS WIRE)--Lantern Pharma Inc.
  • ZacksKrystal Biotech (KRYS) Up 8.5% Since Last Earnings Report: Can It Continue? It has been about a month since the last earnings report for Krystal Biotech, Inc. (KRYS). Shares have added about 8.5% in
  • GlobeNewswireAchieve Life Sciences Announces FDA Acceptance of Cytisinicline New Drug Application for Treatment of Nicotine Dependence for Smoking Cessation Filing based on pivotal Phase 3 ORCA-2 and ORCA-3 clini
  • Insider MonkeyNeurocrine Biosciences, Inc. (NBIX) Beats Estimates on Neurology Drug Demand, Expands Payer Access We recently compiled a list of the 11 Best Pharma Stocks to Invest in for the Long Term. Neurocrine
  • NewsfileOS Therapies Completes Exercise Inducement and Exchange Offer for All Remaining Outstanding Warrants Issued in Connection with December 2024 Financing All remaining holders of outstanding warrants wi
  • NewsfileOS Therapies Provides OST-HER2 Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma Program Update Following FDA End of Phase 2 Meeting Company on track to begin submission of a rolling Biolo
  • ZacksGSK Adds Around $5B in a Month: Here's How to Play the Stock GSK GSK stock has risen 6.4% over the past month, adding nearly $5 billion to its market value. The consistently strong performance of the
  • BioPharma DiveAmgen to invest $600M in new US center; Sanofi drug for ITP approved This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma D
  • ZacksGEHC Launches AI-Powered Vivid Pioneer Cardiac Ultrasound System GE HealthCare GEHC recently unveiled the Vivid Pioneer, its most advanced AI-powered cardiovascular ultrasound system, designed to ele
  • ZacksIs DefenCath Sufficient to Support CorMedix's Long-Term Growth Path? CorMedix’s CRMD lead drug, DefenCath (Taurolidine + Heparin), is currently its only marketed product that generates revenues for t
  • Simply Wall St.NovoCure (NVCR) Is Up 5.4% After Spain Reimburses TTFields Therapy—Has The Bull Case Changed? Spain's Ministry of Health recently made NovoCure's Tumor Treating Fields (TTFields) therapy available th
  • ZacksFDA Identifies ICU Medical's Plum Duo Recall as Serious Type ICU Medical ICUI is currently encountering a recall notice from the FDA for its Plum Duo Infusion System. The recall is for correcting cer
  • NewsfileOS Therapies to Provide OST-HER2 Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma FDA End of Phase 2 Meeting Update on Tuesday, September 2, 2025 New York, New York--(Newsfile Corp. - Aug
  • Insider MonkeyThe FDA Extends the Review Deadlines for Two Submissions by Regeneron Pharmaceuticals (REGN) Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Most Undervalued US Stocks According to Wall S
  • Insider MonkeyH.C. Wainwright Reiterates Buy Rating on IO Biotech, Keeps PT at $14 IO Biotech, Inc. (NASDAQ:IOBT) is one of the 11 Low Price High Volume Stocks to Buy According to Analysts. On August 15, H.C. Wain
  • GlobeNewswireSerina Therapeutics Announces FDA Feedback Supports Registrational Trial Design of SER-252 in Advanced Parkinson’s Disease under 505(b)(2) NDA Pathway - U.S. IND filing planned for Q4 2025 with U.S.
  • Insider MonkeyH.C. Wainwright Remains Bullish on Precigen (PGEN) Precigen, Inc. (NASDAQ:PGEN) is one of the top strong buy stocks under $5 to buy now. H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Bu
  • NewMediaWireNRx Pharmaceuticals (NASDAQ: NRXP) Seeks FDA Ban on Toxic Ketamine Preservative LOS ANGELES, CA - August 25, 2025 (NEWMEDIAWIRE) - NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutic
  • GlobeNewswireValneva Announces FDA’s Decision to Suspend License of Chikungunya Vaccine IXCHIQ® in the U.S. Saint Herblain (France), August 25, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty v
  • Business WireDelcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer QUEENSBURY, N.Y., August 19, 2025--(BUSINESS WIRE)--Delcath Systems,
  • GuruFocus.comPolyPid Ltd (PYPD) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Rising Expenses Cash and Cash Equivalents: $17.4 million as of June 30, 2025. Short Term Deposits: $12 million as of June
  • GlobeNewswireAutonomix Medical, Inc. Finalizes Design Review of First-Ever Intravascular Nerve Sensing Catheter in Key Step Toward U.S. Clinical Studies Microchip-based platform enables real-time nerve mapping an
  • GuruFocus.comAllurion Technologies Inc (ALUR) Q2 2025 Earnings Call Highlights: Strategic Pivot and Cost ... Revenue: $3.4 million for Q2 2025, down from $11.8 million in Q2 2024. Gross Profit: $2.5 million or 74
  • GuruFocus.comGRAIL Inc (GRAL) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... Revenue: $35.5 million, up 11% compared to Q2 2024. Screening Revenue: $34.4 million, up 22% compared to Q2
  • GuruFocus.comTaysha Gene Therapies Inc (TSHA) Q2 2025 Earnings Call Highlights: Regulatory Milestones and ... Research and Development Expenses: $2.1 million for Q2 2025, compared to $15.1 million for Q2 2024. Ge
  • GlobeNewswireMoleculin Reports Second Quarter 2025 Financial Results and Highlights - Continues recruitment and opens US and EU sites for the Phase 2B/3 MIRACLE trial - 20+ additional clinical sites in Europe and
  • GuruFocus.comCapricor Therapeutics Inc (CAPR) Q2 2025 Earnings Call Highlights: Navigating Challenges with ... Cash Position: Approximately $122.8 million as of June 30, 2025. Revenue: $0 for Q2 2025, compared to
  • Business WireAtara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress Tab-cel Prescription Drug User Fee Act (PDUFA) Target Action Date of January 10, 2026 Atara has transferred s
  • PR NewswireCalciMedica Reports Second Quarter 2025 Financial Results and Provides Clinical & Corporate Updates Enrollment ongoing in Phase 2 KOURAGE trial of Auxora™ in acute kidney injury (AKI) with respirator
  • ZacksADMA Beats on Q2 Earnings and Revenues, Asceniv Drives Momentum ADMA Biologics (ADMA) reported better-than-expected results for the second quarter. Adjusted earnings per share of 15 cents beat the Za
  • ZacksCatalyst Pharmaceuticals Q2 Earnings Beat, Firdapse Revenues Rise Y/Y Catalyst Pharmaceuticals CPRX reported adjusted earnings of 68 cents per share for the second quarter of 2025, beating the Zacks
  • GlobeNewswireClearmind Medicine Receives IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center IRB Approval from Hadassah Medical Center Follows FDA IND Clearance and Prio
  • PR NewswireNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Filing of a Citizen Petition with the US Food and Drug Administration Seeking Removal of Benzethonium Chloride from Ketamine Products Sterile ketamin
  • GlobeNewswireNutriband Confirms Record and Pay date for 25% Preferred Stock Dividend as it Targets Filing for FDA Approval ORLANDO, Fla., July 18, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTR
  • Unknown outlet
  • Unknown outlet
  • Unknown outlet
4 more outlets ran the same wire story